PFIZER

PFIZER INC
World Rank (Jan-07-2022)
27
Market Cap (Jan-07-2022)
312.750 Billion USD
World Rank (Sep-01-2021)
36
Market Cap (Sep-01-2021)
258.300 Billion USD
World Rank (Jan-01-2021)
46
Market Cap (Jan-01-2021)
204.600 Billion USD
World Rank (Jan-2020)
37
Market Cap (Jan 1st 2020)
215.483 Billion USD
Annual Revenue in USD
81,288 Million USD
Annual Net Income in USD
21,980 Million USD
Annual Results for Year Ending
Dec-2021
Total Assets in USD
154,230 Million USD
Total Liabilities in USD
90,991 Million USD
Total Equity in USD
63,238 Million USD
Balance Sheet Summary for Period ending
Dec-2020
Headquarters Region / City
New York
Headquarters Country
USA
Headquarters Sub Region
Northern America
Headquarters Continent
Americas
Company Business
Healthcare
Pharmaceutical
HealthCare Products
Biotechnology
Technology
Stock Category
S&P 500
Stock Exchange
NYSE
Company Rank in Country in 2022
Company Rank in USA in 2022 is 18
Rank in Country (Jan-2021)
Company Rank in USA in 2021 is 29
Rank in Country (Jan-2020)
Rank in USA in 2020 is 25
Number of Employees
78,500
Employee Count as on Date
As on May 2021
Chairman
Albert Bourla
CEO:
Albert Bourla
Founders
Charles F. Erhart
Charles Pfizer
Yahoo @ NYSE
Wikipedia
Twitter
Bloomberg
Facebook
Company Website:
Pfizer - Top Pharmaceutical Company
Founded Year
1849
Business Sector:
Top Technology Companies in USA
Top Healthcare Companies in USA
Top Technology Companies in S&P 500
Top Healthcare Companies in S&P 500
Top Pharmaceutical Companies in USA
Top Pharmaceutical Companies in S&P 500
About Company Business:

Pfizer is one of World's Top Pharmaceutical company and its headquarters is in New York, USA. Pfizer Products and Medicines are the results of 1500 scientists overseeing more than 500,000 lab tests and over 36 clinical trials before the first prescription. Pfizer develops medicines from simple diseases to most complex diseases in the world and their products are pharmaceutical drugs, vaccines.

As om 2021, Pfizer  has 79,000 employees.

Pfizer  annual revenue generated for period ending Dec-2021 was 81.28 million USD.

Pfizer  annual net income generated for period ending Dec-2021 was 21.98 million USD.

Total Assets as on Dec-2021 was 181,476 Million USD

 

 

Annual Revenue
PFIZER Annual Revenues for December-2020 ending is 41.91 Billion USD
Annual Operating Income
8.76 Billion USD for Year ending December-2020
Annual Net Income
PFIZER Annual Net Income for December-2020 ending is 9.62 Billion USD
Total Current Assets
PFIZER Total Current Assets as on June-2020 is 46,424 Million USD
Total Assets
PFIZER Total Assets as on June-2020 is 177,934 Million USD
Total Current Liabilities
PFIZER Total Current Liabilities as on June-2020 is 32,723 Million USD
Total Liabilities
PFIZER Total Liabilities as on June-2020 is 113,598 Million USD
Total Equity
PFIZER Total Equity as on June-2020 is 64,336 Million USD
Major Acquisitions

Pfizer acquired Wyeth for 68 Billion USD in 2009.

Annual Results Summary:

Pfizer Inc - Yearly Revenue and Net Profit - in Billion USD:

Year - Ending Revenue Operating Income Net Profit EPS (USD)
Dec-2021 81.28 23.65 21.98 3.93
Dec-2020 41.91 8.76  9.62 1.18
Dec-2019 51.75 13.92 16.27 2.92
Dec-2018 53.65 15.04 11.15 1.90
Dec-2017 52.54 14.10 21.31 4.57
Dec-2016 52.82    7.21  1.18
Balance Sheet Summary

Pfizer Inc - Balance Sheet Summary - in Million USD:

Year Ending: Total Assets Total Liabilities Total Equity
Dec-2021 181,476 104,014 77,462
Dec-2020 154,229 90,991 63,238
Dec-2019 167,489 104,345 63,143
Dec-2018 159,422 96,015 63,407
Dec-2017 171,797 100,489 71,308
Dec-2016 171,615 112,072 59,544
Quarterly Results Summary:

Pfizer Inc - Quarterly Revenue and Net Profit - in Million USD:

Quarter - Ending Revenue Net Profit
Sep-2022 22,638 8,608
Jun-2022 27,742 9,906
Mar-2022 25,661 7,864
Dec-2021 23,838 3,393
Sep-2021 24,094 8,146
Jun-2021 18,977 5,589
Mar-2021 14,582 4,886
Dec-2020 5,947 630
Sep-2020 12.13 2.19
Jun-2020 11.80 3.42
Mar-2020 12.03 3.40
Dec-2019 12.69 (-)0.33  (Loss)
Sep-2019 12.68 7.68
Jun-2019 13.26 5.05
Mar-2019 13.12 3.88
Dec-2018 13.98 (-)0.39 (Loss)
Sep-2018 13.30 4.11
Jun-2018 13.47 3.87
Institutional Investors

Top 30 Institutional Investors in PFIZER as on JUN-30-2022

RANK INSTITUTIONAL HOLDER NAME DATE SHARES HELD CHANGE (SHARES) CHANGE (%) VALUE (IN 1,000S)
1 VANGUARD GROUP INC 6/30/2022 488,445,127 9,379,854 1.96% $22,439,169
2 BLACKROCK INC. 6/30/2022 435,152,528 27,068,406 6.63% $19,990,907
3 STATE STREET CORP 6/30/2022 287,217,028 362,823 0.13% $13,194,750
4 CAPITAL WORLD INVESTORS 6/30/2022 250,126,747 30,250,912 13.76% $11,490,823
5 WELLINGTON MANAGEMENT GROUP LLP 6/30/2022 219,171,647 2,497,346 1.15% $10,068,745
6 GEODE CAPITAL MANAGEMENT, LLC 6/30/2022 108,582,838 3,684,436 3.51% $4,988,296
7 MORGAN STANLEY 6/30/2022 72,548,435 25,173,688 53.14% $3,332,875
8 NORTHERN TRUST CORP 6/30/2022 66,978,348 467,468 0.70% $3,076,985
9 CHARLES SCHWAB INVESTMENT MANAGEMENT INC 6/30/2022 64,122,012 4,293,163 7.18% $2,945,765
10 BANK OF AMERICA CORP /DE/ 6/30/2022 61,777,210 2,779,143 4.71% $2,838,045
11 NORGES BANK 12/31/2021 56,763,604 -2,124,201 -3.61% $2,607,720
12 BANK OF NEW YORK MELLON CORP 6/30/2022 56,341,321 1,708,092 3.13% $2,588,320
13 STATE FARM MUTUAL AUTOMOBILE INSURANCE CO 6/30/2022 53,568,997 0 0% $2,460,960
14 CAPITAL INTERNATIONAL INVESTORS 6/30/2022 49,430,982 10,900,979 28.29% $2,270,859
15 LEGAL & GENERAL GROUP PLC 6/30/2022 42,791,672 1,336,403 3.22% $1,965,849
16 MASSACHUSETTS FINANCIAL SERVICES CO /MA/ 6/30/2022 42,257,600 -1,133,519 -2.61% $1,941,314
17 JPMORGAN CHASE & CO 6/30/2022 41,031,975 7,981,650 24.15% $1,885,009
18 DIMENSIONAL FUND ADVISORS LP 6/30/2022 40,233,015 1,331,272 3.42% $1,848,305
19 DEUTSCHE BANK AG\ 6/30/2022 39,132,177 673,414 1.75% $1,797,732
20 PRICE T ROWE ASSOCIATES INC /MD/ 6/30/2022 34,938,210 -404,839 -1.15% $1,605,061
21 AMUNDI 6/30/2022 27,789,344 2,149,041 8.38% $1,276,642
22 UBS ASSET MANAGEMENT AMERICAS INC 6/30/2022 25,979,571 1,820,095 7.53% $1,193,501
23 ROYAL BANK OF CANADA 6/30/2022 25,361,302 -1,593,788 -5.91% $1,165,098
24 SWISS NATIONAL BANK 6/30/2022 24,393,441 82,500 0.34% $1,120,635
25 WELLS FARGO & COMPANY/MN 6/30/2022 22,899,251 -2,131,535 -8.52% $1,051,992
26 AMERIPRISE FINANCIAL INC 6/30/2022 22,053,718 -560,926 -2.48% $1,013,148
27 PARAMETRIC PORTFOLIO ASSOCIATES LLC 3/31/2022 21,908,327 217,479 1.00% $1,006,469
28 GOLDMAN SACHS GROUP INC 6/30/2022 21,865,861 2,033,150 10.25% $1,004,518
29 FMR LLC 6/30/2022 20,724,644 2,935,073 16.50% $952,090
30 NUVEEN ASSET MANAGEMENT, LLC 6/30/2022 20,629,500 13,528 0.07% $947,719

Comments

Pfizer is expanding Phase 3 Trials to test Covid-19 Vaccine

Pfizer and BioNTech planning to expand phase 3 trials to test Covid-19 vaccine. From initial plan of 30,000 people, now they are planning to conduct trials of Covid-19 vaccine on 44,000 people. They are expecting results by Oct-2020 ending.

 

Sun, 13/09/2020 - 14:58

Share it on Social Media